Dr. Amy Heimberger on Immunotherapeutics in the Context of Glioblastoma
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM). Heimberger says the mechanisms that glioblastoma tumors use for suppression are much more heterogenous than other tumors. She said because of this, oncologists are now studying the effects of targeted the key hubs of tumor-mediated immune suppression.
Heimberger says one target of interest for oncologists is in the secreted protein FGL2. FGL2 is secreted by GBM and regulated several mechanisms of immune suppression. Heimberger says that by targeting FGL2, treatment could be more significant for GBM patients.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
